ESTABLISHED USES

• Severe aplastic anaemia

• Acute lymphoblastic leukaemia (certain subtypes)

• Acute myeloid leukaemia in first complete remission (patient < 50 years old)

• Non-Hodgkin's lymphoma in second complete remission

• Myelodysplasia (patient < 50 years old)

• Multiple myeloma
  

• Acute lymphoblastic leulaemia in first complete remission (certain subtypes)
  

• Solid tumours such as neuroblastoma and testicular cancer

• Severe congenital immunodeficiency
  

• Aplastic anaemia (banked cells only)

• Acute myeloid leukaemia and acute lymphoblastic leukaemia in second complete remission

• Hodgkin's disease in second complete remission

• Thalassaemia

• Chronic myeloid leukaemia

 back to top

EMERGING USES

• Multiple myeloma

• Chronic lymphoblastic leukaemia

• Hodgkin's disease

• Acute myeloid leukaemia

• Non-Hodgkin's disease

• Solid tumours, such as breast, ovarian

• Haemoglobinopathies including:

• Chronic myeloid leukaemia

• Sickle cell anaemia

• Hodgkin's disease in first complete remission

• Thalassemia

• Non-Hodgkin's lymphoma in first complete remission

• Multiple others

• Systemic sclerosis

• Inborn errors of metabolism including:

• Autoimmune pulmonary hypertension

• Osteopetrosis

• Necrotizing vasculititis

• ALL amyloidsis
  

• Rheumatoid arthritis: resistant or complicated

•  Multiple others

• Systematic lupus erthematosus

• Antiphospholipid syndrome

• Cryoglobulinaemia

• Systemic sclerosis variants with pulmonary fibrosis

• Dermatomyositis

• Necrotizing vasculititis

• Multiple sclerosis

• Myasthenia gravis

• Autoimmune thrombocytopenia

• Autoimmune haemolytic anaemia

• Autoimmune neutropenia

• Inflammatory bowel disease

• Autoimmune diabetes mellitus

 back to top

EXPERIMENTAL USES

• Chronic lymphocytic leukaemia

• Amyloidosis

• Renal cell carcinoma

• Other solid tumours

• Breast cancer

• Juvenile chronic arthritis

back to top

PROPOSED USES

•  Acute neural damage

•  Acute neural damage

back to top